Robert C. Bast Jr., M.D.
Robert C. Bast, Jr., M.D.
Vice President for Translational Research
University of Texas
MD Anderson Cancer Center
Dr. Bast is Vice President for Translational Research at The University of Texas M. D. Anderson Cancer Center. His office facilitates translation of new strategies, drugs and devices from the laboratory to the clinic, as well as the movement of human material and data from the clinic to the laboratory. Dr. Bast group coordinates programs to train physician-scientists and clinician-investigators, to facilitate development of multi-investigator grants, to provide instrumental shared resources, to develop faculty inventions and to enhance collaborations with Pharma.
Dr. Bast received his B.A. cum laude from Wesleyan University and his M.D. magna cum laude fromHarvardMedicalSchool. After completing a medical internship at The Johns Hopkins Hospital, he served as a research associate at the National Cancer Institute. Returning toBoston, Dr. Bast completed a medical residency at thePeterBentBrighamHospital and a fellowship in Medical Oncology at the Dana-Farber Cancer Institute. He joined the faculty at Harvard as an Assistant Professor and was subsequently appointed Associate Professor at the Dana-Farber Cancer Institute. Dr. Bast was recruited to theDukeUniversityMedicalCenter in 1984 as Professor of Medicine, Microbiology and Immunology to co-direct the Division of Hematology-Oncology and to serve as Clinical Director of theCancerCenter. In 1987, he became the Director of theDukeComprehensiveCancerCenter and in 1992 he was named Wellcome Clinical Professor of Medicine in honor of R. Wayne Rundles. In July 1994, Dr. Bast was recruited to head the Division of Medicine atM.D.AndersonCancerCenter and to fill the Harry Carothers Wiess Chair for Cancer Research. In 2000, Dr. Bast was appointed Vice President for Translational Research. In 2004, he became the Harry Carothers Wiess Distinguished University Professor for Cancer Research.
Dr. Bast is best known for developing the OC125 monoclonal antibody that led to the production of the CA125 radioimmunoassay. Serum CA125 levels have provided the first generally useful marker for monitoring the course of patients with epithelial ovarian cancer. CA125 is currently being evaluated as one component of a screening strategy for ovarian cancer. Dr. Bast’s early studies focused on the use of immunostimulants and monoclonal antibodies for cancer therapy. Over the last 15 years, Dr. Bast’s group has pioneered in defining molecular alterations in ovarian and breast cancers that might serve as targets for therapy as well as diagnosis. His group discovered ARHI (DIRAS3), a novel ras-related imprinted tumor suppressor gene that regulates growth, motility, autophagy and tumor dormancy. Recent studies have demonstrated that the SIK2 kinase regulates centrosome splitting and paclitaxel sensitivity. Overall, Dr. Bast has published more than 600 articles and chapters and has edited the textbook Cancer Medicine. He has been recognized by the Institute for Scientific Information (ISI) as one of the most frequently cited scientists in his field (top 0.5%). He continues to care for patients with breast and ovarian cancer and has been listed in the Best Doctors of America and in America’s Top Physicians.
